EVALUATION OF INFLAMMATORY BOWEL DISEASE SEVERITY, TREATMENT AND OUTCOMES AMONG PALESTINIAN PATIENTS
No Thumbnail Available
Date
2024-02-01
Authors
Naser, Aya
Journal Title
Journal ISSN
Volume Title
Publisher
An-Najah National University
Abstract
background
Inflammatory bowel disease (IBD) is considered a chronic disease, and it has become more widespread recently. Studies related to it in Palestine are limited. The objectives of this study are to evaluate the severity of the disease, its treatment, and its outcomes among Palestinian patients with inflammatory bowel disease to improve its treatment and follow up.
Method
This cross-sectional study was conducted from August 2022 to March 2023 at An-Najah National University Hospital, Nablus, Palestine. A data collection form was used to collect data from patients’ files and interviews, it was designed to assess IBD severity, treatment, and outcome. The results were analyzed using the Statistical Package for the Social Sciences (SPSS).
Result
This study included 219 patients 53.4% of them were males and 46.6% were females, the duration of illness 1-38 years, the age ranged between 6-86 years. we found that 47.9% patients suffered from ulcerative colitis and 52.1% from Crohn's disease, regarding severity of the disease which was based on clinical and diagnostic characteristics, patients were diagnosed with mild in 26% cases, while 45.2% had moderate, and 28.8% were diagnosed with severe. Moreover, the most common symptoms were bloody diarrhea 63%. Regarding medications, mesalamine was the most common medication used as a primary medication in patients with IBD, at a rate of 74%. for current medications, mesalamine was used by 46.6%, corticosteroid by 22.8%, azathioprine by 41.1%, and biological therapy by 35.2%.
Conclusion
Many patients have severe stages of the disease which affects their daily life. this study shows number of significant associated factors that should be considered when dealing with IBD. Results of the study may help healthcare providers and strategy makers to increase knowledge about IBD patients and its treatment, to improve the quality of life of the IBD patient.